No abstract available.
Adalimumab ; Antibodies, Monoclonal, Humanized

No abstract available.
Adalimumab ; Antibodies, Monoclonal, Humanized

No abstract available.
Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Arthritis, Psoriatic* ; Adalimumab ; Infliximab

No abstract available.
Antibodies, Monoclonal, Humanized ; Humans ; Rectum* ; Cetuximab

No abstract available.
Antibodies, Monoclonal, Humanized ; Bevacizumab ; Cyclophosphamide ; Ovarian Neoplasms

Antibodies, Monoclonal, Humanized ; Humans ; Myocarditis ; Taxus

No abstract available.
Antibodies, Anti-Idiotypic ; Antibodies, Monoclonal, Humanized ; Urticaria ; Omalizumab

PURPOSE: To observe the degree of damage in a 30-gauge injection needle by observing the changes in needle tip following an intravitreal injection with the use of a scanning electron microscope. METHODS: The present study evaluated 11 injection needles collected following the use of an intravitreal injection of bevacizumab. Ten unused injection needles were selected as the control group. Needle examination was performed using a scanning electron microscope. RESULTS: Following 11 intravitreal injections, seven bent needle tips, two stubbed needle tips and two almost normal needle tips were observed following intravitreal injections. In the control group, a single damaged needle tip was observed. CONCLUSIONS: Significant damage to the needle tip was observed following intravitreal injection using a 30-gauge injection needle. The results indicate that needles should be manipulated carefully during an intravitreal injection. Additionally, in the control group where no procedures were performed, a single injection needle with damaged status was found. These results indicate that needles should be replaced in cases in which resistance is perceived during the procedure.
Antibodies, Monoclonal, Humanized ; Electrons ; Intravitreal Injections ; Microscopy, Electron ; Needles ; Bevacizumab

PURPOSE: To clinically establish the effectiveness and safety of bevacizumab on recurrent pterygium. METHODS: Twenty patients with recurrent pterygium were given a subconjunctival injection of 0.3 cc bevacizumab, and were evaluated for periodic clinical results at 1 week, 2 weeks, 4 weeks, and every month thereafter. The patients were also evaluated for clinical results and complications. RESULTS: Of recurrent pterygium patients with bevacizumab injection, the conjunctival injection decreased maximally after 1 to 2 weeks, but significantly increased at 4 weeks (above the lowest level measured at 1 to 2 weeks), and no patient presented conjunctival injection above the pre-injection level at 3 months, except in 2 cases. Two weeks after the injection, ICG anterior segment angiography revealed a significant decrease (30.14+17.69%) in vessel thickness of the pterygium 2 weeks after the bevacizumab injection compared to before the injection. There had been no cases of progression of pterygium, and no ocular or systemic complications due to bevacizumab. CONCLUSIONS: As shown above in the results, subconjunctival injection of 0.3 cc bevacizumab decreased the conjunctival injection and effectively suppressed any further progression of pterygium. Thus, bevacizumab subconjunctival injection appears to be effective in recurrent pterygium treatment instead of surgical methods.
Angiography ; Antibodies, Monoclonal, Humanized ; Glycosaminoglycans ; Humans ; Pterygium ; Bevacizumab

No abstract available.
Adolescent ; Antibodies, Monoclonal, Humanized ; Dermatitis, Atopic ; Humans ; Ustekinumab